Epicutaneous 1-Chloro-2, 4-Dinitrobenzene (DNCB) Patch in HIV Infection.

Inclusion Criteria

Patients must have:

• EITHER HIV negative or documented HIV+ by both the ELISA and Western blot tests.

For HIV+ patients:

• Patients must fail to meet the AIDS-defining criteria.
• CD4 lymphocyte count between 200 - 500 cells/mm3.

Exclusion Criteria

Co-existing Condition:

Excluded:

Patients with obvious ultra violet(UV)-irradiated skin damage in the treatment sites.

Concurrent Medication:

Excluded:

• Patients who are likely to commence antiretrovirals within the 6-month study period.
• Patients using other immunomodulator therapies or other alternative therapies.
• Patients likely to require chemotherapy during the course of the study.

Concurrent Treatment:

Excluded:

• Patients who are likely to require significant UV light exposure during the study period.
• Patients who are likely to require radiation therapy during the course of the study.

Prior Medication:

Excluded:

• Prior exposure to DNCB.
• Patients who have used antiretroviral medications within the previous 3 months.